Trials / Completed
CompletedNCT00648284
Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
An Observational Study to Assess the Impact of Pharmacological Intervention and Life Style Changes in the Reduction of Cardiovascular Disease in Patients With Diabetes Type 2 in Greece
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,100 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.
Conditions
Timeline
- Start date
- 2004-03-01
- First posted
- 2008-04-01
- Last updated
- 2008-10-15
Source: ClinicalTrials.gov record NCT00648284. Inclusion in this directory is not an endorsement.